DACENZA
Therapeutic Class: Anti-Neoplastic
Irreversible EGFR/HER-family tyrosine kinase inhibitor for molecularly selected metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation.
As prescribed by Physician
15 mg, 30 mg, 45 mg Tablet
20–25°C, excursions permitted 15–30°C
